Filing Details
- Accession Number:
- 0001062993-23-016607
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-16 16:59:50
- Reporting Period:
- 2023-08-15
- Accepted Time:
- 2023-08-16 16:59:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1042074 | Cymabay Therapeutics Inc. | CBAY | Pharmaceutical Preparations (2834) | 943103561 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1705745 | Daniel Menold | C/O Cymabay Therapeutics, Inc. 7575 Gateway Blvd., Suite 110 Newark CA 94560 | Vice President, Finance | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-08-15 | 8,500 | $1.06 | 8,500 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-08-15 | 0 | $11.92 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-08-15 | 7,000 | $10.00 | 7,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-08-15 | 0 | $12.13 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2023-08-15 | 8,500 | $0.00 | 8,500 | $1.06 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2023-08-15 | 7,000 | $0.00 | 7,000 | $10.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2026-01-25 | No | 4 | M | Direct | |
| 0 | 2025-01-06 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.64 to $12.27, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $12.27, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in equal monthly installments over the next 36 months.
Billionaire Hedge Funds
